España, septiembre de 2012.- Una nueva forma de abordar el infarto agudo de miocardio (IAM) en sus primeros momentos basada en estudios realizados por investigadores españoles de la RECAVA (Red de Investigación Cardiovascular) es la que recomiendan las nuevas Guías de Actuación en IAM de la Sociedad Europea de Cardiología.
Sorin Group has announced it has received CE mark approval for extended indications of Perceval S, as well as for an entirely re-designed 2nd generation set of implantation accessories. Perceval S is a bioprosthetic valve designed to replace a diseased native or malfunctioning prosthetic aortic valve via open heart surgery with the unique characteristic of allowing sutureless positioning and anchoring at the implantation site.
Madrid, septiembre de 2012.- Según el último estudio realizado por Thomson Reuters sobre el factor de impacto de las principales publicaciones científicas, Journal Citacions Report (JCR), Revista Española de Cardiología (REC) es la revista escrita en lengua española más influyente y más consultada.
Abiomed has received 510(k) clearance from the FDA for a new percutaneous, catheter-based Impella device providing peak flows of approximately four liters of blood per minute. The increased flow is delivered on the same console platform, 9 French catheter, and introducer as the Impella 2.5. This new heart pump will be marketed as the Impella CP (Cardiac Power) within the United States and has been commercially known outside the US as the Impella cVAD.
The Society for Cardiovascular Angiography and Interventions (SCAI) has launched the new SCAI Quality Improvement Toolkit (SCAI-QIT) Appropriate Use Criteria (AUC) and Guidelines app designed to provide information on coronary revascularisation appropriate use criteria.
Madrid, septiembre de 2012.- La soledad está históricamente relacionada con un mayor riesgo de sufrir enfermedad y depresión. La Fundación Española del Corazón (FEC) quiere destacar los resultados de un reciente estudio que relaciona, además, el vivir solo con un aumento de la tasa de mortalidad por causa cardiovascular, especialmente entre los mayores de 45 años.
The PROTECT (Patient Related Outcomes with Endeavor versus Cypher stenting trial) study, which was presented as a late-breaking trial at the annual meeting of the European Society of Cardiology (ESC, 25–29 August, Munich, Germany) and simultaneously published online in The Lancet, failed to fulfil its hypothesis that Medtronic’s Endeavor zotarolimus-eluting stent would be superior to Cordis’ Cypher sirolimus-eluting stent in terms of reducing the rate of definite or probable stent thrombosis.
Elixir Medical has received CE mark approval for its Desyne BD Novolimus Eluting Coronary Stent System for the treatment of coronary artery disease.
Medtronic has announced that it has completed high risk patient enrolment in its CoreValveUS pivotal trial. More than 1,500 patients with severe aortic stenosis who are at high or extreme risk for aortic valve surgery have been included. In addition, Medtronic received FDA conditional approval to begin evaluating the CoreValve System in patients at intermediate risk for open-heart aortic valve replacement as part of the SURTAVI trial (Surgical replacement and transcatheter aortic valve implantation). The company expects to begin US patient enrolment within weeks.
Cardiologists are restricting the use of transcatheter aortic valve implantation (TAVI) to very old or very sick patients at high surgical risk, according to research presented at the ESC Congress on 29 August. The first results of the Transcatheter Valve Treatment (TCVT) Sentinel Pilot registry were presented by registry chairman Carlo Di Mario, London, UK.
First results from the German Aortic Valve Registry (GARY) show that participating centres using transcatheter aortic valve implantation (TAVI) are adhering to current guidelines for patient selection. Data were presented by Friedrich-Wilhelm Mohr, clinic director of the Leipzig Heart Centre, Germany, at a Hot Line session in the ESC Congress (Munich, Germany, 25–29 August 2012)
MUNICH and SAN DIEGO, Aug. 28, 2012 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC) a worldwide leader in precision guided therapy tools, today celebrated the publication of the results of the FAME 2 trial in the New England Journal of Medicine (NEJM). Volcano also announced participation in the next major international functionally-guided studyISCHEMIA that will include the newest PrimeWire® PRESTIGE PLUS Pressure Guidewires.
August 29, 2012 -- Medtronic, Inc. (NYSE: MDT) and Volcano Corporation (NASDAQ: VOLC) today announced that they have entered into a strategic alliance to provide interventional cardiologists, cardiac catheterization laboratory managers and cardiovascular service line directors a robust product offering solution to address the spectrum of clinical need in coronary artery disease.
On 26 August 2012, HeartFlow announced that data from the company’s landmark prospective, international DeFACTO (Determination of fractional flow reserve by anatomic computed tomographic angiography) study were presented by principal investigator James K Min, director of Cardiac Imaging Research at the Department of Medicine, Imaging and Biomedical Sciences at Cedars-Sinai Medical Center in Los Angeles, USA, in a hotline session at the European Society of Cardiology (ESC) meeting in Munich, Germany, and simultaneously published in The Journal of the American Medical Association.
On 28 August 2012, St Jude Medical announced results of the FAME II trial demonstrating that patients with fractional flow reverse (FFR)-guided stenting plus the best available medical therapy had superior outcomes to those treated with medical therapy alone. Results published online in the New England Journal of Medicine (NEJM) and presented during a Hot Line session at the ESC Congress 2012 (European Society of Cardiology) revealed that use of the PressureWire (technology used to measure blood flow restriction in the coronary arteries) yielded an 86% relative risk reduction for unplanned re-admission to the hospital with urgent revascularisation in patients with stable coronary artery disease.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos